NanoEnTek Inc. announced that it expects to receive KRW 10 billion in funding from a group of investors
October 18, 2016
Share
NanoEnTek Inc. (KOSDAQ:A039860) announced a private placement of third unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on October 19, 2016. The transaction will include participation from new investors, Timefolio Private Placement Fund for KRW 900,000,000, Timefolio The Time-M Hedge Fund for KRW 500,000,000, Timefolio The Time-H Hedge Fund for KRW 500,000,000, Timefolio The Time-A Hedge Fund for KRW 600,000,000, Timefolio The Time-Q Hedge Fund for KRW 500,000,000, Synergy Partners Co., Ltd. for KRW 2,500,000,000, PineAsia Season III Mezzanine Private Investment Hedge Fund [balanced bond] for KRW 2,600,000,000, PineAsia Season III Mezzanine PF [balanced bond] for KRW 400,000,000, C Square Mezzanine Plus Specialty PEF 3 for KRW 300,000,000, C Square Mezzanine Plus Specialty PEF 4 for KRW 300,000,000, C Square Mezzanine Plus Specialty PEF 5 for KRW 400,000,000, GB Synergy Mezzanine Private Fund Investment Trust E-1 [Bond Balanced] for KRW 100,000,000, and GB Synergy Mezzanine Private Equity Investment Hedge Fund K-1 [Bond Balanced] for KRW 400,000,000. The company will issue bonds at par. The bonds carry zero coupon rate and zero yield to maturity. The bonds are convertible into common shares of the company at fixed conversion price of KRW 5,958 per share. The conversion period is from October 21, 2017 to September 21, 2021. The bonds will mature on October 21, 2021. The payment and subscription date is October 21, 2016. The transaction has been approved by the board of directors of the company.
NanoenTek,Inc. is a Korea-based company mainly engaged in the manufacturing of point of care testing (POCT) medical equipment and biotechnology research equipment. The Companyâs products consist of Countess, EVE and ADAM, which are cell counting systems; NEON, which are gene delivery systems; JuLI, which are fluorescence microscopes, and chips, which are consumables of cell counting systems. It also provides diagnostic medical equipment, such as FREND systems, which are quantitative immunoassay analyzing devices; ADAM-rWBC, an analytical device for counting the number of residual white blood cells (rWBCs) in leukoreduced blood products, and others. The Company distributes its products within domestic market and to overseas markets.
NANOENTEK, INC. 
